Interim Report 2026
Filed with HKEX · Stock code 8158 · · 42 pages · English and Chinese
Summary by 6ix AI
The report includes unaudited condensed consolidated financial statements, highlighting revenue, gross profit, and profit before tax figures compared to the previous year. It also provides insights into the company's financial position, including total assets and liabilities as of mid-year. The report emphasizes the responsibilities of the directors regarding the accuracy and completeness of the information presented.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
China Regenerative Medicine International Limited on 6ix
Earlier from China Regenerative Medicine International
- CEO Mr. Chen Chunguo Holds a Meeting with Government Official of Shaanxi Xixian New Area - Discuss the Strategic Deployment of Regenerative Medicine Industry Develop Hi-tech Cosmeceuticals Industrial Park
- R&D Team of “Acornea” Invited to Share the R&D and Application Experience of the First Chinese Bio- engineered Cornea at Oxford
- China Regenerative Medicine International: “Acornea” expands clinical applications Completed FDA registration
- Financial Secretary of HK SAR Paul Chan Mo-po Leads Delegation on Visit to the Group Encourages to Promote the Innovative Technology Development of Regenerative Medicine
- Fund Invested to Acquire U.S Cosmeceuticals Brand-Obagi
Later from China Regenerative Medicine International
- Letter to Registered Shareholder - New Arrangements on Dissemination of Corporate Communications and Reply Form
- Letter to Non-registered Shareholder - New Arrangements on Dissemination of Corporate Communications
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Resignation of auditor
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
Follow China Regenerative Medicine International into a list and get an email when it puts out news.
Follow China Regenerative Medicine International